로딩 중…
StockDiggingStockDigging

Embecta Corp.

EMBC· NASDAQ
$3.13+1.13%
2026-06-18

Price Chart

Embecta Corp.-66.68%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$185M
Revenue$1.04B
Net Income$112M
Total Assets$1.03B
Net Assets$551M
Employees1,850
Value
P/E1.66x
P/B0.34x
P/S0.18x
EV/EBITDA4.08x
FCF Yield110.41%
Profitability
ROE20.33%
ROA10.87%
Op. Margin29.78%
Revenue Growth-14.36%
Earnings Growth-117.45%
Financial Health
Debt Ratio300.71%
Total Debt$1.36B
FCF$205M
Cash$185M
Current Ratio2.46x
Net Debt/EBITDA3.52x
Dividend
Div. Yield19.04%
Div. Growth1.68%
Payout Ratio25.42%
Performance
1Y Return-66.68%
1M Return7.76%
From 52W High-79.35%
1Y MDD-80.53%
Trading
Volume2,111,997 shares
Trading Value$7M
Per Share
EPS$2.36
BPS$-10.35

Company Info

CEO Mr. Devdatt Kurdikar Ph.D.
Employees 1,850
HQ Parsippany, United States

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.